Fol News

Tutti gli approfondimenti
Tutte le notizie

Moderna (MRNA) = VACCINO x Coronavirus

  • Creatore Discussione permabull
  • Data di inizio
preso un cippetto sembra fra le maggiori titolate per il corona vaccino
 
forse stasera a borse chiuse fanno l annuncio...
 
che i primi test umani funzionano....ma è solo una mia opinione
 
Mm sembra uno di quei titoli rifugio quando l'indice va male
 
forse lunedì ci sarà qualche dato

Frequency of solicited local reactogenicity adverse events (AEs) [ Time Frame: Through 7 days post-vaccination ]
Frequency of solicited systemic reactogenicity adverse events (AEs) [ Time Frame: Through 7 days post-vaccination ]
Grade of solicited local reactogenicity adverse events (AEs) [ Time Frame: Through 7 days post-vaccination ]
Grade of solicited systemic reactogenicity adverse events (AEs) [ Time Frame: Through 7 days post-vaccination ]

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection - Full Text View - ClinicalTrials.gov
 
Quindi la notizia è deludente rispetto alle aspettative.
 
Venduta adesso in gain del 5%
 
Buon trend a seguito anche dei primi risultati legati alla sperimentazione sull'uomo.
Speriamo prima di tutto per la salute di tutti noi.
 
vedo male in After 27.95 -12.65 (-31.16%)
 
We buongiorno ma scomparsi tutti? E mo che si fa? Io ho venduto con un bel gainuccio vorrei rientrare, aspetto?

Ps consigliatami da un utente di altro forum...:D
 
Moderna's coronavirus vaccine candidate advances to next stage of testing
MARKETWATCH 5:06 PM ET 4/27/2020
Symbol Last Price Change
MRNA 48.05 -2.45 (-4.85%)
QUOTES AS OF 04:00:00 PM ET 04/27/2020
Moderna Inc. (MRNA) said late Monday its candidate for a coronavirus vaccine will get to be evaluated further. The biotech company said it has submitted a new-drug application with the U.S. Food and Drug Administration to evaluate the vaccine candidate, mRNA-1273, in a more extensive study if supported by safety data from an initial study. The phase 2 study is expected to begin in the second quarter, Moderna(MRNA) said. That will evaluate the safety and any adverse reactions and immune responses of two mRNA-1273 vaccinations given 28 days apart, the company said. Each person participating in the study will be assigned to receive a placebo or different doses of the vaccine candidate, Moderna(MRNA) said. The plan is to enroll 600 healthy adults and older adults in two cohorts, Participants will be followed through 12 months after the second vaccination, Moderna(MRNA) said. "Submitting this (investigative new-drug application) is an important next step in the clinical development of our mRNA vaccine against SARS-CoV-2, and we are moving rapidly to potentially address this global health emergency," Moderna's(MRNA) Chief Medical Officer Tal Zaks said in a statement. A third phase could begin in the fall of 2020, the company said. Moderna(MRNA) is one ofnearly two dozen U.S. companies working on a vaccine (http:// MarketWatch Site Logo stand-2020-03-06)against COVID-19 as the disease has killed more than 200,000 worldwide. (MarketWatch: Stock Market News - Financial News - MarketWatch story/covid-19-case-tally-298-million-cases-206803-deaths-2020-04-27)

-Claudia Assis; 415-439-6400; AskNewswires@dowjones.com


(END) Dow Jones Newswires
04-27-201706ET
Copyright (c) 2020 Dow Jones & Company, Inc.
 
serenella6 ha scritto:
Moderna's coronavirus vaccine candidate advances to next stage of testing
MARKETWATCH 5:06 PM ET 4/27/2020
Symbol Last Price Change
MRNA 48.05 -2.45 (-4.85%)
QUOTES AS OF 04:00:00 PM ET 04/27/2020
Moderna Inc. (MRNA) said late Monday its candidate for a coronavirus vaccine will get to be evaluated further. The biotech company said it has submitted a new-drug application with the U.S. Food and Drug Administration to evaluate the vaccine candidate, mRNA-1273, in a more extensive study if supported by safety data from an initial study. The phase 2 study is expected to begin in the second quarter, Moderna(MRNA) said. That will evaluate the safety and any adverse reactions and immune responses of two mRNA-1273 vaccinations given 28 days apart, the company said. Each person participating in the study will be assigned to receive a placebo or different doses of the vaccine candidate, Moderna(MRNA) said. The plan is to enroll 600 healthy adults and older adults in two cohorts, Participants will be followed through 12 months after the second vaccination, Moderna(MRNA) said. "Submitting this (investigative new-drug application) is an important next step in the clinical development of our mRNA vaccine against SARS-CoV-2, and we are moving rapidly to potentially address this global health emergency," Moderna's(MRNA) Chief Medical Officer Tal Zaks said in a statement. A third phase could begin in the fall of 2020, the company said. Moderna(MRNA) is one ofnearly two dozen U.S. companies working on a vaccine (http:// MarketWatch Site Logo stand-2020-03-06)against COVID-19 as the disease has killed more than 200,000 worldwide. (MarketWatch: Stock Market News - Financial News - MarketWatch story/covid-19-case-tally-298-million-cases-206803-deaths-2020-04-27)

-Claudia Assis; 415-439-6400; AskNewswires@dowjones.com


(END) Dow Jones Newswires
04-27-201706ET
Copyright (c) 2020 Dow Jones & Company, Inc.
Clicca per espandere...

è arrivato il suo momento
 
Devi accedere o registrarti per poter rispondere.
Indietro